Researcher receives grant to develop new breast cancer treatment

Backed by funds through the UC Venture Lab, RNA Nanotherapeutics has recently successfully scaled up production of its nanoparticles, a major step toward commercialization.

But before the startup can offer its treatment to the public, it must complete an investigational new drug development study that includes additional safety and toxicity studies.

After the investigation into the development of new drugs is complete, the company could receive approval from the US Food and Drug Administration to start clinical trials.

To complete the research, RNA Nanotherapeutics needs to raise approximately $5 million to $10 million. While well versed in grant writing, Zhang said his experience in the Venture Lab helped him further develop his approach, which he hopes will help attract more investors and award grants.

“We need to advance the science, take our learning to the clinical trial phase, and for that we need funding,” Buse said. “We have a great opportunity to gradually use RNA nanoparticles to extend the lives of loved ones.”

Buse and Zhang’s goal is to have a commercially available product that will be more effective in treating breast cancer in the next three to five years. They also believe the process could be adapted to treat other cancers and diseases as well.

“We want to move this to clinics as soon as possible,” Zhang said. “The only step to get us there is to get commercial investments and more grants to support our business for a successful outcome of clinical trials.”

Leave a Comment